STOCK TITAN

Co-Diagnostics, Inc. to Participate in the Piper Sandler 35th Annual Healthcare Conference in New York City on November 30, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) will be presenting at the Piper Sandler 35th Annual Healthcare Conference in New York City, New York on November 30, 2023. The presentation will discuss the progress on its forthcoming Co-Dx™ at-home and point-of-care PCR platform. The Company will also be participating in one-on-one meetings with institutional investors.
Positive
  • None.
Negative
  • None.

SALT LAKE CITY, Nov. 29, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the Piper Sandler 35th Annual Healthcare Conference in New York City, New York on November 30, 2023.

The presentation will be conducted by Co-Diagnostics CEO Dwight Egan at 12:10 PM EST and will include a discussion of Company progress on its forthcoming Co-Dx™ at-home and point-of-care PCR platform*.

The Company will also be participating in one-on-one meetings with institutional investors, which can be arranged via representatives of Piper Sandler.

*The Co-Dx PCR at-home and point-of-care platform (including the PCR Home™, PCR Pro™, mobile app, and all associated test kits) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to locate genetic markers for use in applications other than infectious disease.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-participate-in-the-piper-sandler-35th-annual-healthcare-conference-in-new-york-city-on-november-30-2023-302000365.html

SOURCE Co-Diagnostics

FAQ

What is Co-Diagnostics, Inc.'s ticker symbol?

The ticker symbol for Co-Diagnostics, Inc. is CODX.

What event will Co-Diagnostics, Inc. be presenting at?

Co-Diagnostics, Inc. will be presenting at the Piper Sandler 35th Annual Healthcare Conference in New York City, New York.

Who will be conducting the presentation for Co-Diagnostics, Inc.?

The presentation will be conducted by Co-Diagnostics CEO Dwight Egan.

What will be discussed in the presentation?

The presentation will include a discussion of Company progress on its forthcoming Co-Dx™ at-home and point-of-care PCR platform.

What is the status of the Co-Dx PCR at-home and point-of-care platform?

The Co-Dx PCR at-home and point-of-care platform is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

Co-Diagnostics, Inc.

NASDAQ:CODX

CODX Rankings

CODX Latest News

CODX Stock Data

23.60M
29.79M
6.7%
13.96%
0.72%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
SALT LAKE CITY